A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
A phase 2 trial of durvalumab and pemigatinib in gallbladder cancer and other biliary tract cancers, run by Mehmet Akce, now recruiting.
Overview
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement is a phase 2 interventional study registered as NCT06728410 by Mehmet Akce, with a registry enrolment figure of 38 participants, started 2026-01-27 and due to reach its primary completion in 2027-07. Interventions recorded: Pemigatinib, Durvalumab. Conditions listed: Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation. Gallbladder cancer is named in the registry entry: "5. Histologically diagnosed locally advanced unresectable or metastatic intrahepatic cholangiocarcinoma with FGFR-2 fusion or rearrangement detected by Clinical Laboratory Improvement Act (CLIA)-certified assays includin". Sites: United States. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Shares Pemigatinib, Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab and the tag gallbladder-deep-dive.
- TrialAlternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Shares Pemigatinib, Ampullary cancer (ampulla of Vater), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialPemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma
Shares Pemigatinib, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.
- TrialThe Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialPD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment
Shares Ampullary cancer (ampulla of Vater), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialA Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialImmunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialTesting A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
Shares Ampullary cancer (ampulla of Vater), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.